As BRAF is downstream of RAS in the MAPK/ERK signaling pathway, mutated BRAF is assumed to have the same resistance to the anti-EGFR agent as to the RAS-mutated colon tumor [10]. The gene discussed is EGFR; the disease is colonic neoplasm.